TrialBlood2012
CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900.
Mithat Gönen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
45 papers cite it
this paperpooled ittrialcites it